ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0880

Health Information Use by SLE Patients Pre and During COVID-19

Francesca Cardwell1, Susan Elliott2, May Choi3, Ricky Chin3, Yvan St.Pierre4, Leigha Rowbottom5, Murray Urowitz6, Guillermo Ruiz-Irastorza7, Sasha Bernatsky8, Michelle Petri9, Susan Manzi10, Christine Peschken11, Rosalind Ramsey-Goldman12, Paul R Fortin13, Jungmin Shin14, Sang-Cheol Bae15, Jiacai Cho16, Anselm Mak17, John Hanly18, Anca Askanase19, Juanita Romero-Diaz20, Romina Nieto21, Bernardo A. Pons-Estel22, Ian N. Bruce23, Daniel Wallace24 and Ann Clarke5, 1University of Waterloo, Burlington, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 4Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 5University of Calgary, Calgary, AB, Canada, 6Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, 7Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, 8McGill University, Montréal, QC, Canada, 9Johns Hopkins University School of Medicine, Baltimore, MD, 10Allegheny Health Network, Wexford, PA, 11University of Manitoba, Winnipeg, MB, Canada, 12Northwestern University, Chicago, IL, 13CHU de Quebec - Universite Laval, Québec City, QC, Canada, 14Hanyang University Hospital, Seoul, Republic of Korea, 15Hanyang University Medical Center, Seoul, Republic of Korea, 16National University Health System (NUHS), Singapore, Singapore, 17National University of Singapore, Singapore, Singapore, 18Dalhousie University, Halifax, NS, Canada, 19Columbia University Medical Center, New York, NY, 20Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, 21Hospital Provincial de Rosario, Rosario, Argentina, 22Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina, 23University of Manchester, Manchester, United Kingdom, 24Cedars-Sinai, Los Angeles, CA

Meeting: ACR Convergence 2021

Keywords: COVID-19, health behaviors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The spread of COVID-19 misinformation is especially serious for individuals with complex diseases like SLE; conflicting and/or unfounded information can complicate a patient’s health decision making and exacerbate stress. We assessed how SLE patients access and trust health information pre and during COVID-19.

Methods: Canadian and international patients fulfilling the ACR or Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria for SLE were recruited from 15 observational SLE research cohorts, and patients self-reporting SLE were recruited through five patient advocacy organizations. Participants completed an online survey from June 2020-April 2021 regarding the sources of health information they accessed in the 12 months preceding (pre 03/11/2020) and during the COVID-19 (post 03/11/2020) pandemic. We calculated the percentage of patients accessing each source of information, their preferred sources, and the level of trust in each source. McNemar tests were used to compare frequencies pre and post 03/11/2020 in the Canadian and international samples.

Results: 845 Canadian and 1090 international (Asia n=201, Europe n=324, Latin America n=118, US n=447) patients completed the survey (40.4% and 21.0% response rates, respectively); 78.0% were recruited through SLE research cohorts, 92.7% were female, 35.2% reported non-white race/ethnicity, mean age at diagnosis was 32.0 years (SD 13.3) and mean disease duration was 16.6 years (SD 12.0). 76.6% of participants had completed post-secondary education, and 2.1% reported a positive COVID-19 test. Canadian and international patients accessed news media more frequently during vs pre pandemic (44.6% of Canadians accessed sometimes/often/always pre vs 52.1% during; 59.8% of international participants accessed pre vs 68.9% during), while access to family physicians, lupus specialists, pharmacists and alternative care providers decreased in both samples during the pandemic (Table 1). Lupus specialists and family physicians were ranked the most preferred information sources (Table 2) and considered the most trustworthy (Table 3) pre and during the pandemic. News media was more preferred post vs pre 03/11 (Table 2), yet was considered less trustworthy in Canada (44.5% rated online news media as somewhat/very trustworthy pre vs 41.8% post) and internationally (43.0% pre vs 40.2% post) during COVID-19 (Table 3). In both samples, patient advocacy organizations were accessed less frequently pre and during COVID-19 than other less preferred and trusted sources (e.g., peers, social media), and trust in advocacy organizations decreased during the pandemic in both Canadian and international samples by 4.1% and 5.0%, respectively.

Conclusion: Although lupus specialists and family physicians were ranked as the most preferred and trustworthy health information sources, patients accessed these sources less frequently during the pandemic and accessed news media, a less trusted source, more frequently. To increase accessibility to preferred and trusted sources, virtual visits should be promoted where not already in place. This research will improve existing information dissemination pathways valued by SLE patients.

Table 1: Health Information Source Frequency of Access, Pre and Post March 11, 2020

Table 2: Preferred Health Information Sources, Pre and Post March 11, 2020

Table 3: Trustworthiness of Health Information Source, Pre and Post March 11, 2020


Disclosures: F. Cardwell, None; S. Elliott, None; M. Choi, MitogenDx, 1, 2; R. Chin, None; Y. St.Pierre, None; L. Rowbottom, None; M. Urowitz, GlaxoSmithKline, 2, 5, 6, UCB, 2, Lilly, 6, AstraZeneca, 2; G. Ruiz-Irastorza, None; S. Bernatsky, None; M. Petri, Alexion, 1, Amgen, 1, Astrazeneca, 1, 5, Aurinia, 5, 6, Eli Lilly, 5, Emergent Biosolutions, 1, Exagen, 5, Gilead Biosciences, 2, GSK, 1, 5, IQVIA, 1, Idorsia Pharmaceuticals, 2, Janssen, 1, 5, Merck EMD Serono, 1, Momenta Pharmaceuticals, 2, PPD Development, 1, Sanofi, 2, Thermofisher, 5, UCB Pharmaceuticals, 2; S. Manzi, Astra Zenecs, 2, 5, Cugene, 2, Eli Lilly, 2, Exagen, 2, 5, 10, UCB, 2, GSK, 2; C. Peschken, AstraZeneca, 2, GlaxoSmithKline, 2, Eli Lilly, 2; R. Ramsey-Goldman, None; P. Fortin, Lilly, 1, AbbVie, 1, AstraZeneca, 1; J. Shin, None; S. Bae, None; J. Cho, None; A. Mak, None; J. Hanly, None; A. Askanase, GSK, 2, 5, AstraZeneca, 1, 5, Amgen, 1, Aurinia, 2, Abbvie, 1, Pfizer, 5, Eli Lilly, 5, Idorsia, 5; J. Romero-Diaz, None; R. Nieto, None; B. Pons-Estel, Janssen, 5, Glaxo Smith Kline, 6; I. Bruce, None; D. Wallace, GlaxoSmithKline, 2, 6, Eli Lilly and Company, 2, 6, AstraZeneca, 2, 6, Aurunia, 2, 6, EMD Serono, 2; A. Clarke, AstraZeneca, 2, GSK, 6, BMS, 2, Exagen Diagnostics, 2.

To cite this abstract in AMA style:

Cardwell F, Elliott S, Choi M, Chin R, St.Pierre Y, Rowbottom L, Urowitz M, Ruiz-Irastorza G, Bernatsky S, Petri M, Manzi S, Peschken C, Ramsey-Goldman R, Fortin P, Shin J, Bae S, Cho J, Mak A, Hanly J, Askanase A, Romero-Diaz J, Nieto R, Pons-Estel B, Bruce I, Wallace D, Clarke A. Health Information Use by SLE Patients Pre and During COVID-19 [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/health-information-use-by-sle-patients-pre-and-during-covid-19/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/health-information-use-by-sle-patients-pre-and-during-covid-19/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology